N-quinazolin-2-yl-acetamide | 103264-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-quinazolin-2-yl-acetamide
• 英文别名: N-Chinazolin-2-yl-acetamid；N-quinazolin-2-ylacetamide
• CAS: 103264-36-4
• 化学式: C₁₀H₉N₃O
• 分子量: 187.201
• InChiKey: HQRFZXWTQMMHRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氯喹唑啉 在 氨 、 水 作用下， 生成 N-quinazolin-2-yl-acetamide
  参考文献：
  名称：

  679.磺胺甲酰胺衍生物：衍生自2-和4-氨基喹唑啉和1-氨基酞嗪的化合物

  摘要：

  DOI：

  10.1039/jr9560003509

文献信息

• QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS
  申请人：Muthuppalniappan Meyyappan

  公开号：US20090325987A1

  公开（公告）日：2009-12-31

  The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明提供了喹唑啉二酮衍生物作为TRPA（瞬时受体电位亚家族A）调节剂。具体来说，本文描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、病况和/或疾病。本文还提供了制备本文描述的化合物的方法、用于合成的中间体、药物组合物以及治疗或预防由TRPA1调节的疾病、病况和/或疾病的方法。
• NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF
  申请人：Moinet Christophe

  公开号：US20110077228A1

  公开（公告）日：2011-03-31

  The invention relates to 21-keto triterpene compounds of formula (I): wherein R 1 , X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.

  该发明涉及式(I)的21-酮三萜化合物：其中R1、X和Y如本文所定义，并且其药用可接受的盐和溶剂化合物。这些化合物表现出显著的抗HIV活性。因此，该发明还涉及通过向需要此类治疗的受试者施用式(I)的化合物或其药用可接受的盐或溶剂，来预防或治疗HIV感染的方法。
• US7951814B2
  申请人：——

  公开号：US7951814B2

  公开（公告）日：2011-05-31
• US8431556B2
  申请人：——

  公开号：US8431556B2

  公开（公告）日：2013-04-30
• [EN] QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS<br/>[FR] DÉRIVÉS DE QUINAZOLINE DIONE EN TANT QUE MODULATEURS DE TRPA1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2010004390A1

  公开（公告）日：2010-01-14

  The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA 1. Formula (I).